levofloxacin has been researched along with dabigatran in 1 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (dabigatran) | Trials (dabigatran) | Recent Studies (post-2010) (dabigatran) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 3,887 | 261 | 3,490 |
| Protein | Taxonomy | levofloxacin (IC50) | dabigatran (IC50) |
|---|---|---|---|
| Solute carrier family 22 member 2 | Homo sapiens (human) | 4.7 | |
| Prothrombin | Homo sapiens (human) | 0.0046 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 8.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
1 other study(ies) available for levofloxacin and dabigatran
| Article | Year |
|---|---|
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |